I am not sure why this item was introduced as "moderately disturbing". If you will permit me, I will explain what it is, since I use it regularly. (I have no stock nor other biased affiliation with the company or product.) The product first came on the market in 1998, over 10 years ago. It has a well-established place in the treatment of chronic wounds. It is not the only product in the category of "living cell therapies" for chronic wounds. The other product is Dermagraft, similar, and likewise around for nearly 10 years. When Apligraf first came out, it was promoted as skin-graft-in-a-box. It is not. It is allogeneic material (recipients will reject it), and thus it does not "take" to the body like an autogenous skin graft. In its earliest years, when the company was promoting it as a skin graft, it got some high profile press because it was put to good use as readily available biological coverage for burn victims of the 9-11-2001 twin towers catastrophe. The company that makes it, Organogenesis, partnered with pharma giant Novartis for marketing and product management, and under them, they listened to customers who told them it was not skin grafts in a box, and they redefined its marketing for chronic wounds. The product management has been back in the hands of Organogenesis for about 3 or 4 years now.
The material is essentially a poly-pharmaceutical packaged in a living material. The raw materials come from donated foreskins. Extensive safety testing is done. Pure extracted fibroblasts are put into cell culture, where they do their business and re-form a collagen matrix equivalent to normal dermis. After that, pure keratinocytes are cultured on top of the dermis, and an epidermis forms. The product is shipped in its petri dish, as a circle of 44 sq cm area. The Gizmodo article shows a picture of it. As a living material, its procurement and handling are a bit different than most medical devices, but it is easy to get and apply.
The juvenile cells in the material make a broad spectrum of growth factors and other biochemicals which have a positive pro-proliferative effect on wounds. The role for this material is for chronic and pathological wounds. The company got its market approval and indications from the FDA for studies done on diabetic and venous ulcers, but the material is useful for chronic and pathological ("cap") wounds of any cause. Like anything else, it does not work for all wounds or patients, but it is fairly predictable, and its results can be rather dramatic. When a cap wound of whatever cause has been treated to the point that disease is quiet, inflammation is gone, and the wound should be healing but it is not, then that is when wound stimulatory therapies are applied. There are several available, and Apligraf has been one of the flagship products in this category for 10 years now. Many wounds which simply will not budge no matter what will take off and heal once this is applied.
Organogenesis has its first new product coming out soon, for oral mucosa and gingiva, so perhaps that is why they are trying to stir up some attention with articles like the one quoted. However, it is not Brave New World nor Coma nor any other meat factory. It is just on the leading edge of biological therapeutics in the 21st century. And if Slashdotters want to make lots of jokes as they often do, like "put Viagra in the petri dish to grow more", well, we've already heard them all.
(All very timely, since I just gave a presentation on this last week (and have been for 8 years). If you want to learn more, I posted a copy of the presentation on the website I use for posting talks and presentations and whatnot. This particular talk has a mix of my slides and company slides. It is NOT yet annotated with full text on each slide, so some will just be pictures and you will have to infer what you can, but text should be coming one of these days:
Again, I have no investment nor bias here, I just use this stuff in practice because it works and it's an important product.)